BioHouston

BIO-Europe 2008

Tue, 13 May 2008 21:50:23 GMT

BIO-Europe 2008 Start Date: 17-Nov-08 0:00 AM End Time: 19-Nov-08 0:00 AM Location: m:con Congress Center Rosengarten Speaker: Event Details: BIO-Europe brings together international decision-makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities, workshop participation, and private, pre-scheduled one-to-one meetings. Investment and collaboration opportunities developed in prior BIO- Europe conferences have produced many highly successful business partnerships. Highlights include: State-of-the-art partnering software that enables participants to select the most suitable potential partners. The system - industry-specific, web based and interactive - is uniquely suited for the needs of biotech and pharma companies. Selected biotechnology, mid-sized & big pharmaceutical companies present their products/technologies and corporate missions in 15 minute presentations. High level faculty on panels and workshops, in...

Texas Life Science Conference

Tue, 04 Mar 2008 19:54:07 GMT

Texas Life Science Conference Start Date: 5-Nov-08 0:00 AM End Time: 7-Nov-08 12:00 PM Location: The Brown Foundation Institute of Molecular Medicine, Houston, TX 77030 Speaker: Event Details: The Texas Life Science Conference is Texas premier venture conference, the most comprehensive showcase of cutting edge research and innovative entrepreneurs in the state. The 2008 conference will build on the 2007 format, highlights of which include: 50 companies and technologies presented to over 315 conference attendees ranging from industry luminaries and key venture capitalists to leaders of emerging biotech companies, research scientists, and entrepreneurs Over $6 billion in current funds represented by attending investors The Michael E. DeBakey Life Science Award for the Texas undiscovered life science company with the highest potential to commercialize an important product You...

16th Annual BioPartnering Europe

Fri, 25 Jan 2008 18:05:42 GMT

16th Annual BioPartnering Europe
Start Date: 12-Oct-08 0:00 AM
End Time: 14-Oct-08 12:30 PM
Location: Queen Elizabeth II Conference Centre
Speaker:

Event Details:

BioPartnering Europe (BPE) was first held in London in 1993 as a partnership between the U.S. Commercial Service and Technology Vision Group LLC to bring about closer ties between American and European biotechnology companies. From the beginning, BPE has attracted the support of leading pharmaceutical, biotechnology, financial and service companies who have all contributed to making this one of the leading independent partnering events in the world. BPE has a high rate of sponsor retention, which signals its prominent role in the annual conference calendar for many industry leaders.

More details to come soon.

For registration and more information, click here.

Queen Elizabeth II Conference Centre

Broad Sanctuary, Westminster

London United Kingdom

BioContact Qubec 2008

Tue, 04 Mar 2008 20:07:46 GMT

BioContact Québec 2008
Start Date: 1-Oct-08 0:00 AM
End Time: 3-Oct-08 12:00 PM
Location: Château Frontenac, Quebec, Quebec G1R4P5
Speaker:

Event Details:

BioContact Québec 2008 will make available private meeting rooms for one-on-one sessions. These meetings will be offered in consecutive 30-minute periods. Senior representatives from presenting biopharmaceutical companies and our strategic partners will be on hand for biopartnering sessions.

This year’s event will offer four presentation sessions (Block I - IV). More than 150 biopharmaceutical companies, coming from Canada, the United States, Asia and Europe, will be presenting in different sectors of activities (diagnostics, therapeutics and services) and disciplines such as:

Cancer
Cardiology
Drug Delivery Systems
Endocrinology / Metabolism
Genomics / Proteomics
Immunology / Infectiology
Medical Technologies
Neurobiology
Services
Virology
Others

For more information and to register, click here.

Château Frontenac

1 rue des Carrieres

Quebec, Quebec Canada G1R4P5

BioPharm America 2008

Fri, 14 Mar 2008 20:10:44 GMT

BioPharm America 2008 Start Date: 9-Sep-08 0:00 AM End Time: 10-Sep-08 0:00 AM Location: Grand Hyatt Hotel, Atlanta, GA 30305 Speaker: Event Details: BioPharm America is where biotech industry partnerships get started. Based on the same winning formula used in EBD Group’s distinguished European partnering conferences BIO-Europe and BIO-Europe Spring®, BioPharm America is expected to become the premier stand-alone bio-pharma partnering event in North America. With a clear focus on generating one-to-one meetings for attendees, BioPharm America offers an unrivalled opportunity for participants across the entire biotech value-chain to identify and enter into strategic relationships. As part of the EBD family of events, which includes the world’s largest stand alone biotech partnering conference BIO-Europe, BioPharm America applies a unique and proven model for helping companies get partnerships started. Why attend BioPharm America? Use the state-of-the-art...

Advances in Tissue Engineering 2008

Fri, 02 May 2008 15:17:39 GMT

Advances in Tissue Engineering 2008 Start Date: 13-Aug-08 0:00 AM End Time: 16-Aug-08 0:00 AM Location: Rice University - Duncan Hall, Houston, TX 77005 Speaker: Event Details: Advances in Tissue Engineering 2008 16th Annual Short Course August 13 through 16, 2008 Rice University, Houston, Texas Focusing on advances in the science and technology of tissue engineering and featuring leading scientists from Rice University, the Texas Medical Center, industry, and other institutions. The course will survey the latest knowledge and technologies in the world of patient-specific therapeutics - from transplantation of cells and tissues to artificial organs. COURSE FEATURES The latest on patient-specific therapeutics featuring speakers from academia, medical research, and industry. Topics will include cell adhesion, adhesion molecules, growth factors, extracellular matrix analogs, polymer scaffolds, cell transplantation, nanobiotechnology. Other topics...

Breakfast Forum

Wed, 14 May 2008 21:12:05 GMT

Breakfast Forum
Start Date: 6-Aug-08 7:30 AM
End Time: 6-Aug-08 9:00 AM
Location: M. D. Anderson South Campus Research Building II, Houston, TX 77054
Speaker:

Event Details:

Save the date!

Our featured speaker for the August Breakfast Forum is Read Montague, Ph.D., Professor in the Department of Neuroscience at Baylor College of Medicine, Director of the Human Neuroimaging Lab and Director of the Center for Theoretical Neuroscience.

Dr. Montague's work focuses on computational neuroscience - the connection between the physical mechanisms present in real neural tissue and the computational functions that these mechanisms embody.

More details to come soon!

Sponsorship for the August Breakfast Forum available...please contact Keisha Curtis at 713-979-9212.

M. D. Anderson South Campus Research Building II

7435 Fannin Street

Houston, TX US 77054

Breakfast Forum

Wed, 14 May 2008 21:04:07 GMT

Breakfast Forum
Start Date: 24-Jun-08 7:30 AM
End Time: 24-Jun-08 9:00 AM
Location: M. D. Anderson South Campus Research Building II, Houston, TX 77054
Speaker:

Event Details:

Save the date!

Our featured speaker for the June Breakfast Forum is Huda Zoghbi, M.D., Professor at Baylor College of Medicine and Investigator at Howard Hughes Medical Institute.

Dr. Zoghbi research interests include genetic and cell biological approaches to explore the pathogenesis of Rett syndrome and autistic spectrum disorders, polyglutamine neurodegenerative diseases, and to study genes essential for normal neurodevelopment.

More details to come soon!

Sponsorship for the June and August Breakfast Forum available...please contact Keisha Curtis at 713-979-9212.

M. D. Anderson South Campus Research Building II

7435 Fannin Street

Houston, TX US 77054

BIO 2008

Fri, 29 Feb 2008 16:50:39 GMT

BIO 2008
Start Date: 17-Jun-08 0:00 AM
End Time: 20-Jun-08 0:00 AM
Location: San Diego Convention Center, San Diego, CA 92101
Speaker:

Event Details:

The 2008 BIO International Convention will help expand the biotech innovations that help heal, fuel, and feed the world. Be a part of it!

Vital Connections await You at BIO

Connect with and influence public officials, policy makers, biotechnology leaders, and industry colleagues for better business and regulatory climate and industry growth. Lean how myBIO can help connect you.
Address business issues important to you. Review overview of our education program.
Further your investments and innovations via partnering.
View showcased technology at the BIO Exhibition.
Research hot biotechnology development sites.

For more information and to register online, visit www.bio2008.org

San Diego Convention Center

111 W. Harbor Drive

San Diego, CA 92101

Update on the New Texas A&M Institute for Preclinical Studies

Wed, 14 May 2008 21:32:16 GMT

Update on the New Texas A&M Institute for Preclinical Studies Start Date: 11-Jun-08 11:30 AM End Time: 11-Jun-08 1:00 PM Location: BioHouston Offices, Houston, TX 77054 Speaker: Event Details: Update on the New Texas A&M Institute for Preclinical Studies Theresa W. Fossum D.V.M., M.S., Ph.D., is a Professor of Surgery and holds the Tom and Joan Read Chair in Veterinary Surgery at Texas A&M University. She is a world renowned surgeon and serves as the Director for Cardiothoracic Surgery and Biomedical Devices in the Michael E. DeBakey Institute at TAMU. She was recently appointed Director of the new Texas A&M Institute for Preclinical Studies, a $70 million venture at TAMU which will promote public-private partnerships to speed the development of medical devices and drugs. Dr. Fossum’s leadership was integral in conceptualizing and funding this Institute. Dr. Fossum has authored numerous articles on chylothorax and other respiratory and surgical diseases. She is the...

President Bush, Congressional Leaders Award DeBakey Nation's Highest Civilian Honor

noemail@biohouston.org — Wed, 23 Apr 2008 15:30:00 GMT

April 23, 2008 -- Its all gold for Dr. Michael E. DeBakey. In the grand Rotunda of the U.S. Capitol, surrounded by Congressional leaders, friends and colleagues, Baylor College of Medicines renowned leader humbly accepted the Congressional Gold Medal, the nations highest civilian honor, from President George W. Bush and the leaders of Congress. See CSpan coverage. My first thought of course is to express my deep-seated and humblest sense of gratitude for this high honor you have afforded me, DeBakey said during the ceremony. Since receiving this award, my cup runneth over. The medal, designed by sculptor-engraver Don Everhart of the U.S. Mint, was commissioned after both the U.S. Senate and U.S. House of Representatives approved legislation supporting the award for the pioneering heart surgeon. President Bush signed the final bill in October of last year. Throughout U.S. history, the Congressional Gold Medal has been awarded sparingly, in recognition of the tremendous...

23-Apr-08 10:30 AM

SBIR/STTR Reauthorization Act Approved

Thu, 17 Apr 2008 17:00:00 GMT

The US House of Representatives passed HR 5819, the "SBIR/STTR Reauthorization Act," by a vote of 369 yeas to 43 nays. This bill reauthorizes the Small Business Innovation Research Grant program and modifies the eligibility rules affecting venture capital backed companies for receiving SBIR grants. It will increase access to critical, early-stage sources of funding for small businesses, including small biotechnology firms, thus facilitating economic growth, job creations, new breakthrough therapies for patients in need, and American economic competitiveness in the global economy.

The Bill which was introduced by Congresswoman Nydia M. Velázquez (D - NY), contains a provision that changes the definition of a small business from the current definition of "independently owned" to include businesses owned up to 49.9 percent by a venture capital firm. Title II of the act amends Sec. 9 (e) of the Small Business Act, which is specific to the SBIR program.

According to Genomeweb.com the bill would, "reauthorize the programs through 2010 and would give Congress time to examine how the programs are working. The bill also would increase funding levels, raising Phase I awards from $100,000 to $300,000 and Phase II awards from $750,000 to $2.2 million, to reflect the rising costs of high-tech research. The authorization also increases the SBIR program's flexibility by allowing cross-agency awards, letting applicants apply directly for Phase II funding, and loosening eligibility for awards to include small businesses that are backed by venture capital funding. The bill expands the requirements for databases of recipients and it requires interoperability and accessibility between databases in order to allow for better congressional oversight."

17-Apr-08 12:00 PM

Texas Makes Top 5 Biotech Regions

Fri, 22 Feb 2008 22:00:00 GMT

HOUSTON, February 22, 2008 - Texas has been named for the first time as one of the Top 5 regions in the world for biotechnology economic development efforts in the annual rankings compiled by the newsletter FierceBiotech.

The primary reason cited for Texas' rise in the rankings is ratification of the state's $3 billion in funding for cancer research by Texas voters last Fall. The bond initiative will allow the Texas legislature to authorize up to $3 billion in bonds over ten years on behalf of a newly formed Cancer Research and Prevention Institute.

"We believe that this honor is recognition of the progress that has been made over the last 5 years in the growth of a thriving life science industry in Houston," said BioHouston President and CEO Jacqueline Northcut. The Houston region now has over 140 life science companies, double the number that existed here in 2003. To see the complete article, click on the following links: Article 1 Article 2

22-Feb-08 4:00 PM

KCIs Therapeutic Support Systems Business Announces Agreement with The MED Group

noemail@biohouston.org — Tue, 13 May 2008 17:30:00 GMT

May 13, 2008 - Kinetic Concepts, Inc., a global medical technology company with leadership positions in advanced wound care and therapeutic support systems, today announced that it has entered into a three-year agreement with The MED Group, a nationwide network of independently-owned home medical equipment (HME), respiratory and mobility companies. Under the terms of the agreement, The MED Group, which has more than 340 member companies and more than 1,000 operating locations nationwide, will be KCIs preferred HME provider network manager and will provide KCI therapeutic support systems referral sources with an efficient and high-quality service to facilitate transfer of patients to the home while ensuring a quicker delivery, more efficient set-up and better patient outcomes. KCI is very pleased to partner with The MED Groups network of independent home medical equipment dealers who have a great reputation for reliable service and high-quality patient care, said Lynne Sly, Global...

Repros Therapeutics Inc. Announces That Proellex Shows No Adverse Cardiac Effects In A Pilot Trial

noemail@biohouston.org — Mon, 12 May 2008 15:00:00 GMT

May 12 - Repros Therapeutics Inc. (NasdaqGM:RPRX) today released encouraging results from its pilot study of the potential for adverse cardiac events associated with administration of doses of Proellex up to four times higher than the intended marketed dose. The study was designed to assess the potential for QT prolongation, an indicator of potential adverse cardiac effects and a major safety consideration for the FDA. Study Results In preparation for conducting a thorough QT study (TQT), Repros has completed a pilot trial dosing healthy female volunteers for seven days with Proellex 200 mg. Formal QT studies are dosed for five days. This Proellex dose is 4 to 8 times the dose shown to be effective in our uterine fibroid and endometriosis trials. Subjects all had baseline electrocardiograms (ECGs) and blood tests for safety and were dosed with Proellex 200 mg daily for 7 days. ECGs were done at baseline and 2 hours after dosing on days 1, 3, 5, and 7. In addition Proellex...

VGX Pharmaceuticals Signs Multi-Year Production Agreement with the United Kingdom Cystic Fibrosis Gene Therapy Consortium

noemail@biohouston.org — Mon, 12 May 2008 14:00:00 GMT

VGX Pharmaceuticals today announced that the Company has signed a multi-year supply agreement to provide plasmid DNA to support the ongoing toxicology and clinical trials of the United Kingdom Cystic Fibrosis Gene Therapy Consortium comprising over 80 scientists and clinicians in Edinburgh, London and Oxford dedicated to the search for effective gene therapy to the lungs of those with Cystic Fibrosis. Under the terms of the agreement, VGX will provide multiple batches of a CFTR product to support clinical studies planned to run through 2010. If all options are exercised, several hundred grams of plasmid DNA will be provided, making this agreement one of the largest contracts for non-viral gene therapy products ever undertaken. Alan Larsen, Director of Research at the Cystic Fibrosis Trust, said, The CF Trust has committed over £30 million to the Consortiums cutting edge work culminating in a phase II clinical trial planned for 2009, and we are proud to be leading the world in gene...

Evestra, Inc., a Drug Company Focused on Womens Health Issues, Launched by Southwest Foundation for Biomedical Research

noemail@biohouston.org — Mon, 12 May 2008 13:00:00 GMT

May 12 - One of the Southwest Foundation for Biomedical Research’s longest running departments is being spun off as a private, for-profit business enterprise based on the massive body of work the department has accumulated in female reproductive and related health issues. SFBR president John Kerr, who first envisioned the concept, said the new company, Evestra Inc., is receiving all of the assets, personnel, and scientific know-how of the Foundation’s Organic Chemistry Department, an internationally recognized research group in steroid chemistry, together with start-up funding from SFBR. In addition to funding provided by SFBR, which will initially be the majority shareholder of the new company, Evestra is raising a first round of financing primarily from San Antonio-area investors. Evestra is being built on the department’s 30-plus years’ experience in the discovery and synthesis of novel steroid compounds used in a wide range of female healthcare applications, including...

ULURU Inc. Announces the Launch Plan for Altrazeal(TM)

noemail@biohouston.org — Thu, 08 May 2008 15:00:00 GMT

May 8 -- ULURU Inc. today announced the Companys launch plan for Altrazeal(TM) and the commercial availability of the product commencing the week of May 19, 2008. Altrazeal(TM) is the first wound care dressing to be developed from our nanoparticle aggregate technology. It is an easy to apply and remove powder hydrogel that in the presence of body fluids rapidly converts to a gel material which fills and seals the wound, promoting an optimal moist healing environment and reduces the need for multiple dressing changes. The Altrazeal(TM) launch meeting, including the training of our sales force, has been conducted during the past two weeks. As part of the training, our sales organization attended the American Burn Association (ABA) Annual meeting in Chicago last week where Altrazeal(TM) was demonstrated. The response from the physicians and nurses to the product was very positive and it was seen as a potentially significant improvement to the treatment and patient care of burn victims....

ArthroCare Announces Patients Treated for Chronic Tendinosis with TOPAZ(R) Highly Satisfied Study Shows

noemail@biohouston.org — Wed, 07 May 2008 15:00:00 GMT

May 07, 2008-- ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, today announced results from its five-year study evaluating the effectiveness of the TOPAZ MicroDebrider to treat common tendon disorders, and concluded patients who had the minimally invasive procedure were highly satisfied with the procedure and continue to experience pain relief. Five-year study results were presented last month at the Arthroscopy Association of North America (AANA) Annual Meeting in Washington D.C. Initiated in 2003, Radiofrequency Microtenotomy for Epicondylitis: Five-Year Follow-up and Proposed Mechanism of Action evaluated the outcome of 82 patients treated for chronic tendinosis using the TOPAZ MicroDebrider. Assessment of pain relief was monitored over a period of one to five years for each patient and 95 percent of patients reported good to excellent results. All patients had symptoms of intractable medial and lateral epicondylitis where...

LC Sciences and DNAVision form Strategic Marketing Alliance

noemail@biohouston.org — Tue, 06 May 2008 16:00:00 GMT

May 6, 2008 – LC Sciences announced today that it has entered into a strategic marketing alliance with DNAVision to increase accessibility to its custom microRNA profiling service and enhance both its customer and technical service to researchers in Europe. LC Sciences’ microRNA profiling service is powered by µParaflo® microfluidic technology and makes use of flexible custom microarrays for expression profiling as well as discovery of novel small RNAs and validation of predicted microRNAs. DNAVision, specialized in molecular biology, provides a wide range of genetic services and products to the pharmaceutical, food, and biotechnology industries. We are very excited about this alliance with DNAVision, clearly one of the quality leaders of microarray and other molecular biology services, says Chris Hebel, Director of Business Development at LC Sciences. Although we are currently serving customers globally from our headquarters in the U.S., we felt is was important to extend our reach...

OncoVista Innovative Therapies Announces Submission of Request for Pre-IDE Determination Meeting with FDA for AdnaGens AdnaTest Breast Cancer Device for Detection of Circulating Breast Tumor Cells

noemail@biohouston.org — Tue, 06 May 2008 15:00:00 GMT

OncoVista Innovative Therapies Inc., a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies, announced the submission of a request to the U.S. Food and Drug Administration for a pre-IDE determination meeting for its AdnaGen AdnaTest Breast Cancer device for the detection of circulating breast tumor cells. AdnaGen is a subsidiary of OncoVista and focuses on the development of innovative tumor diagnostics by utilizing its proprietary technology for the detection and analysis of rare cells. OncoVista’s Chief Executive Officer, Alexander L. Weis, Ph.D., commented: We are very pleased to have submitted this package to the FDA. The AdnaTest is intended for use as a prognostic test for women with metastatic breast cancer, in whom the presence of circulating tumor cells is associated with decreased progression-free survival and decreased overall survival and as such can be of tremendous benefit in determining those patients who can best...

Kinetic Concepts, Inc. Closes Private Sale of Convertible Senior Notes Due 2015 Pursuant to Full Exercise of Over-Allotment Option

noemail@biohouston.org — Fri, 02 May 2008 15:00:00 GMT

May 2, 2008--Kinetic Concepts, Inc. today announced the closing of the private sale of an additional $90 million aggregate principal amount of its 3.25% convertible senior notes due 2015 pursuant to the exercise in full of the over-allotment option granted to the initial purchases of the notes. This brings the total amount of the notes issued to $690 million. The coupon on the notes is 3.25% per year on the principal amount. Interest will accrue from April 21, 2008, and is payable semi-annually in arrears on April 15 and October 15 of each year, beginning October 15, 2008. The notes will mature on April 15, 2015, unless previously converted or repurchased in accordance with their terms. The notes are not redeemable by KCI prior to the maturity date. Upon conversion, holders will receive cash up to the aggregate principal amount of the notes being converted and shares of KCI common stock in respect of the remainder, if any, of KCIs conversion obligation in excess of the...

ArthroCare(R) Establishes Direct Sales Representation in Scandinavia

noemail@biohouston.org — Thu, 01 May 2008 15:00:00 GMT

May 1, 2008--ArthroCare(R) Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced today that it has acquired OrtoConcept Scandinavia, a medical device distributor based in Aarhus, Denmark, and specializing in the distribution of sports medicine and spine devices to surgeons throughout Denmark, Norway and Sweden. The acquisition of OrtoConcept supports ArthroCares strategic objective of direct representation in key markets outside the United States. It further accelerates long term revenue growth potential, controls in-market focus and brand awareness while enhancing the operating income of the companys international business, said Sten Dahlborg, senior vice president and general manager of international operations for ArthroCare. The establishment of direct sales representation in Scandinavia through OrtoConcepts extremely strong customer relations within the orthopedic community, experienced personnel and an exceptionally customer-oriented...

Post-Doctoral Research Fellow

Mon, 12 May 2008 15:00:00 GMT

Title: Post-Doctoral Research Fellow Description: This individual will have the unique opportunity to utilize their scientific skills in the environment of an innovative life sciences company. This person will have responsibility in conducting daily R&D experiments that are critical to project deadlines. You will work closely with the Chief Scientific Officer to assist with experiments, meet deadlines, and generate formal reports. This fellow will have the ability to publish and gain experience in an industrial scientific lab setting. Technical applications include basic laboratory techniques with strong emphasis in immunohistochemistry, fluorescence imaging, western blot and flow cytometry analysis, RNA analysis. We are looking for someone who is a good team player, meticulously detailed and organized, and has good communication skills. Required Experience: Bachelor’s degree and Doctorate degree Experience in oncology related research is preferred Experience in hematology...

Senior Research Scientist

Mon, 12 May 2008 14:00:00 GMT

Title: Senior Research Scientist Description: This individual will have the unique opportunity to utilize their scientific skills in the environment of an innovative life sciences company. This person will have responsibility in conducting daily experiments that are critical to project deadlines. You will work closely with the Chief Scientific Officer to assist with experiments, meet deadlines, and generate formal reports. Technical applications include basic laboratory techniques with strong emphasis in immunohistochemistry, fluorescence imaging, western blot and flow cytometry analysis. We are looking for someone who is a good team player, meticulously detailed and organized, and has good communication skills. Required Experience: Bachelor’s degree and Doctorate degree Experience in oncology related research is preferred but not required Experience in hematology research is a plus This Job Requires the Follow Skills: Writing and verbal communication skills are required ...

Scientist/Sr. Scientist

Fri, 09 May 2008 15:00:00 GMT

Title: Scientist/Sr. Scientist Description: AM Biotechnologies is seeking MS- or PhD-level laboratory scientist with a protein and DNA chemistry/biochemistry background who will work as part of our science team to develop innovative bead-based thioaptamer technologies for research, diagnostic, and therapeutic applications. Qualified candidates will have strong laboratory experience, a strong hands-on skill set, and a desire to devote most of their time to experimental efforts. The successful candidate will enjoy working in the laboratory, be creative and forward thinking, approach challenges with an innovative attitude, enjoy solving technical problems and methodically exploring all plausible avenues for success. Importantly, the candidate must be willing to learn and have a strong work ethic. Note that reimbursement of relocation expenses is not available for this position. Required Experience: MS, PhD, or Doctorate in biochemistry, biophysics, molecular biology, or nucleic...

Database Administrator I (EI DA 25030)

Thu, 08 May 2008 13:00:00 GMT

Title: Database Administrator I (EI DA 25030) Description: Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease located in The Woodlands Texas. We are systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. We have identified and validated more than 100 targets with promising profiles for drug discovery. Our physiology-based approach to understanding gene function and our use of knockouts to model expected drug action are designed to identify new ways to treat major human diseases and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. We are currently recruiting for a Database Administrator I. This...

Senior Scientist, Proteomics

Mon, 05 May 2008 21:00:00 GMT

Title: Senior Scientist, Proteomics Description: This position is a key link between BayPoint’s collaborative research services, new product development and business development. Reporting to the Vice President, Operations, duties center on hands-on management of proteomic analyses, data reduction, data interpretation and report generation. Further duties involve working with clients to design experiments and present results. Required Experience: Requires Ph.D. in Molecular or Cellular Biology and 3+ years of biotech/pharmaceutical experience. This Job Requires the Follow Skills: The successful candidate will demonstrate a working knowledge of bioinformatic analysis of genomic and proteomic data. Familiarity with diagnostic development is considered a plus. Applicant should be a highly motivated and able to work independently. Excellent verbal and written skills are required Education Required: Ph.D. Planned Duration of Employment: Full Time Position reports to: Vice...

Vivarium Technician I (VT 25179)

Mon, 05 May 2008 19:00:00 GMT

Title: Vivarium Technician I (VT 25179) Description: Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease located in The Woodlands Texas. We are systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. We have identified and validated more than 100 targets with promising profiles for drug discovery. Our physiology-based approach to understanding gene function and our use of knockouts to model expected drug action are designed to identify new ways to treat major human diseases and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. We are currently recruiting for a Vivarium Technician I. This position will...

Research Scientist, Proteomics

Mon, 05 May 2008 19:00:00 GMT

Title: Research Scientist, Proteomics
Description: This position is a key member of BayPoint’s collaborative research services and product development team. Duties will center on conducting high-throughput proteomic experiments. Experience with current proteomic analysis methods and automation will be a plus. Required Experience: Requires B.S. in Molecular Biology or related field with 5+ years relevant industrial or academic experience. Experience with robotic microarray production and processing is desirable..
This Job Requires the Follow Skills: Applicant should be a highly motivated, exhibit careful attention to detail and able to work independently. Excellent verbal and written skills are required.
Education Required: B.S.
Planned Duration of Employment: Full Time
Position reports to: Vice President, Operations

Contact info:

George Martin (Add to Contacts)
(510) 681-8314

BayPoint Biosystems

401 Colusa Avenue

El Cerrito, CA United States of America

Research Associate/Assistant (TV RA 23712)

Mon, 05 May 2008 15:00:00 GMT

Title: Research Associate/Assistant (TV RA 23712) Description: Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease located in The Woodlands Texas. We are systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. We have identified and validated more than 100 targets with promising profiles for drug discovery. Our physiology-based approach to understanding gene function and our use of knockouts to model expected drug action are designed to identify new ways to treat major human diseases and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. We are currently recruiting for a Research Associate/Assistant. Duties will...

Regulatory Submissions Manager (RSM 23165)

Mon, 05 May 2008 15:00:00 GMT

Title: Regulatory Submissions Manager (RSM 23165) Description: Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease located in The Woodlands Texas. We are systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. We have identified and validated more than 100 targets with promising profiles for drug discovery. Our physiology-based approach to understanding gene function and our use of knockouts to model expected drug action are designed to identify new ways to treat major human diseases and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. We are currently recruiting for a Regulatory Submissions Manager. This...

Clinical Project Manager (CPM 23894)

Mon, 05 May 2008 15:00:00 GMT

Title: Clinical Project Manager (CPM 23894) Description: Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease located in The Woodlands Texas. We are systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. We have identified and validated more than 100 targets with promising profiles for drug discovery. Our physiology-based approach to understanding gene function and our use of knockouts to model expected drug action are designed to identify new ways to treat major human diseases and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. We are currently recruiting for a Clinical Project Manager. This position will be...

BioHouston Blog

Thu, 15 May 2008 17:48:23 GMT

M. D. Anderson Receives $35 Gift for Cancer Prevention May 15, 2008 The Dan L. Duncan Family Foundation has given The University of Texas M. D. Anderson Cancer Center $35 million—the institution’s largest gift to the cancer prevention program and its second-largest gift in its 67-year history. The funds will be used to establish the Dan Duncan Family Institute for Cancer Prevention and Risk Assessment. The Duncan family’s generosity will enable M. D. Anderson to study the incidence and determinants of cancer in medically underserved and minority communities. A major element of the Duncan Family Institute will address cancer-related behavioral and genetic risk factors in medically underserved communities to better develop cancer prevention strategies and ultimately reduce cancer-related deaths in this rapidly growing segment of our population. The gift also will allow M. D. Anderson to recruit additional researchers and clinicians to implement new or enhance current...

Board of Directors

Wed, 14 May 2008 21:55:36 GMT

Executive Committee Chairman Malcolm Gillis, Ph.D. University Professor and Ervin K. Zingler Professor of Economics Rice University Welcome Letter Vice-Chairman John Mendelsohn, M.D. President The University of Texas M.D. Anderson Cancer Center Secretary and Treasurer Bruce Given, M.D. Healthcare Products Consultant Bruce Given Consulting Steven C. Currall, Ph.D. Vice Dean of Enterprise, Professor and Head (Chair) of Department of Management Science and Innovation, Faculty of Engineering Sciences, University College London; Visiting Professor of Organisational Behaviour and Entrepreneurship (Joint appointment with University College London), Faculty Co-Director, Institute of Technology, London...

BioHouston Breakfast Forum

Wed, 14 May 2008 21:48:57 GMT

June 24, 2008
7:30 AM - 9:00 AM

M. D. Anderson South Campus Research Building II

7435 Fannin Street

Houston, TX 77054

Save the date!

Our featured speaker for the June Breakfast Forum is Huda Zoghbi, M.D., Professor at Baylor College of Medicine and Investigator at Howard Hughes Medical Institute.

More details to come soon!

Sponsorship for the June and August Breakfast Forum available...please contact Keisha Curtis at 713-979-9212.

Capital Development

Tue, 13 May 2008 21:58:44 GMT

Houston is the home to the largest medical center in the world. With over $1.5 billion in annual academic research investments and over 140 life science companies, the region has attracted venture capitalists from across the nation to invest in the growing life science industry in Houston. Texas has also become a hot spot for venture capital investments as a result of the recent approval of the $3 bilion cancer research insitute by Governor Rick Perry, which will distribute up to $300 million in annual grants over the next decade. Listed below are resources for biotech firms, ranging from funds to relevant conferences. Texas Emerging Technology Fund Gulf Coast RCIC Match-Making Meetings SBIR/STTR Support for Emerging Companies Venture Capital Firms National Industry Conferences S3 Ventures is an early-stage technology investor focusing...

BioHouston Newsletter

Fri, 09 May 2008 14:02:04 GMT

BioHouston Newsletter--May 9, 2008 Events & Announcements Breakfast Forum--Texas Newest Venture Fund - Santé Ventures presents The Early Stages of Venture Capital in Texas--May 14--Sponsored by Mayer Brown LLP Life Science Technology Venture Forum--May 15, 2008 BioProducts: Coming Down the Pipeline, A Texas Opportunity--May 21-22 Association of Bioscience Financial Officers National Conference--June 3-6 BIO International Convention--June 17-20 Advances in Tissue Engineering 2008--August 13 - 16--BioHouston members receive discounted registration BioPharm America 2008--September 9-10 Mark your calendars for the 2008 Texas Life Science Conference--November 5, 6, & 7--Sponsorship opportunities available...please contact Keisha Curtis at 713.979.9212 2008 Christopher Columbus Fellowship Foundation $25,000 Homeland Security Award--Nominations due May 23rd News Updates ULURU Inc. Announces the Launch Plan for Altrazeal(TM) ArthroCare...

Members & Associates

Mon, 05 May 2008 21:15:01 GMT

We are grateful to our members and contributors for their generous suppport. All of BioHoustons events and programs are designed to benefit our member institutions and strengthen life science companies in the Houston area. We are happy to report that our membership is growing as more contributors join us to build Houstons life science industry. Many of your colleagues have already joined BioHouston as Members or Associates. We represent more than 120 biotechnology and life science companies, academic institutions, healthcare orgnaizations, service providers and philanthropic organizations in the Houston region. The organization is growing by leaps and bounds as the people of Houston realize the importance of this developing economic engine for the region. We are helping to lead the most innovative and dynamic industry in the world by helping our Members and Associates find continuing success and opportunities. We invite you to join us in helping to create a vibrant life science...

Associate Advisory Board

Mon, 05 May 2008 21:13:21 GMT

Dawn Miller AIG Ngu Morcho AlphaDev Mark Shumbera Aptamed Paul R. Morico Baker Botts LLP Charles Szalkowski Baker Botts LLP Meg Boulware Baker McKenzie LLP Gray Hancock British Consulate-General Laura Capper CAP Resources Gwen Wagner CenterPoint Energy Steven M. Plumb Clear Financial Solutions, Inc. Michael E. Novelli Cypressbrook Company Dan Watkins, Ph.D. DFJ Mercury Debbie Pennington Economic Development Alliance for Brazoria County Carole Faig Ernst & Young LLP Jim Meador Fairway Medical Technologies John M. Farrell FKP Architects, Inc. Michael Clements Frost...

Education & Workforce

Fri, 02 May 2008 18:32:58 GMT

Texas in Top 5 Regions in the World for Biotechnology As one of the top 5 regions in the world for biotechnology, the presence of life science careers in Texas is growing, especially in the Houston region. Home to the Texas Medical Center, Houston has the largest medical center in the world and offers a wide range of educational opportunities and careers in the life sciences. Need a job? Click here to search our job board. Looking to fill open positions? Click here. EDUCATION The institutions in the Houston/Galveston offers extensive programs in biodefense and infectious disease, cardiovascular medicine, genetics/genomics, nanotechnology, and oncology. If you are unsure of what path to take in your career in the life sciences, visit H.O.T. Jobs to view position that is best for you. Specific points include: areas of specialization licensure certification educational programs work environment length of tranining professional associations ...

5th Annual Chili Cook-Off

Fri, 04 Apr 2008 16:00:35 GMT

March 28, 2008 12:00 PM - 5:00 PM BioHouston Offices 2555 Holly Hall Street This years teams brought tons of food to share with attendees, including turkey legs, hot dogs,, kabobs, fruit plates, sausage on a stick, and more! Getting ready for the Chili Cook-Off... Encysive Pharmaceuticals wins Best Booth for Survivor Encysive Having fun in the limbo contest Dan Monticello (far left), President of Molecular LogiX, poses with his team, Chili LogiX Janel Wang of Pharmaceutical Services Corporation, PSChili, poses for the camera Setting up for the jalapeño eating contest Cooling down with milk and water after a competitive contest of jalapeño eating! Janet Varela of Kelly Scientific Resources, Kellys Crows Nest Chili, enjoying the Cook-Off This years Chili Cook-Off saw several four-legged friends who also enjoyed the event, especially the many hot dogs and sausages that coincidentally fell on the ground We are grateful to our...

BioHouston Resource Center (BRC)

Thu, 20 Mar 2008 17:40:51 GMT

THE BIOHOUSTON RESOURCE CENTER Start-ups today need to generate data demonstrating the commercial potential of their products to access significant funding sources. More than ever, start-ups need access to facilities and resources to develop their projects and generate data to get to the next funding event. Without accessible facilities, start-up companies expend scarce resources on leasing and building out laboratory space, purchasing furniture and equipment, and busying themselves with starting up and managing a life science lab. Located one mile south of the Texas Medical Center, the BioHouston Resource Center (BRC) makes it easier and more affordable for start-up companies to walk into the lab and get to work producing data, by providing access to wet lab bench space, shared equipment, and the offices and tools that start-up companies need. The BioHouston Resource Center is constantly seeking lab equipment, materials, and monetary donations. If you would like to donate...

Strategic Planning Initial Test

noemail@biohouston.org — Wed, 16 Jan 2008 16:00:00 GMT

Objectives: BioHouston will use this data to prepare for the future.

Release Date: 16-Jan-08 10:00 AM
Expiration Date: 15-Apr-08 10:00 AM

Survey Test 1

noemail@biohouston.org — Wed, 16 Jan 2008 16:00:00 GMT

Objectives: This is a test survey

Release Date: 16-Jan-08 10:00 AM
Expiration Date: 15-Apr-08 10:00 AM
Test Survey, please take as you would a regular survey.

Lorem ipsum survey

noemail@biohouston.org — Wed, 10 Oct 2007 22:00:31 GMT

Objectives:

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diem nonummynibh euismod tincidunt ut lacreet dolore magna aliguam erat volutpat. Ut wisis enim ad minim veniam, quis nostrud exerci tution ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis te feugifacilisi.

Duis autem dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit au gue duis dolore te feugat nulla facilisi.

Ut wisi enim ad minim veniam, quis nostrud exerci taion ullamcorper suscipit lobortis nisl ut aliquip ex en commodo consequat. Duis te feugifacilisi per suscipit lobortis nisl ut aliquip ex en commodo consequat.Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diem nonummy nibh euismod tincidunt ut lacreet dolore magna aliguam erat volutpat.

Ut wisis enim ad minim veniam, quis nostrud exerci

Release Date: 10-Oct-07 5:00 PM
Expiration Date: 10-Jan-08 5:00 PM

Ut wisis enim ad minim veniam, quis nostrud exerci

Lorem ipsum

2007-10-10T22:00:31Z

Instructor: Instructor

Lorem ipsum